INS and type 2 diabetes mellitus: While certain oral agents like SGLT-2 inhibitors may benefit patients with obesity, and others, such as metformin, require caution in renal impairment, this study primarily focuses on comparing overall effectiveness and safety profiles of insulin versus oral therapies in uncontrolled T2DM [11].